The company hasn’t said. It will depend if they give us interim results or wait for the final GLP report. I suspect that we might get interim results given they need to raise capital to support the PEACH trial. Feb/March would be my best guess.
One thing I hope ILA have done is the analysis on the early doses so they know everything is on track. It would be cheaper to do all the analysis in one batch at the end, but this comes with a lot of risk if the PK/PD doesn’t match the original formulation.
Ann: Approval to commence dosing 3rd cohort of ISLA-101 SAD study, page-13
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
